News

Sandoz announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for marketing authorization of…
Read More...

CutisPharma announced that it has been acquired by NovaQuest Capital Management. As a part of the transaction, Goldman Sachs Specialty Lending Group has provided financing to further…
Read More...

Novo Nordisk announced that the US Food and Drug Administration (FDA) approved updates to the prescribing information (PI) for Tresiba (insulin degludec injection) 100 U/mL, 200 U/mL to…
Read More...

Pfizer Inc. announced results from a Phase 4 study evaluating the efficacy and safety of CHANTIX/CHAMPIX (varenicline) for smoking cessation in nicotine dependent adolescents 12-19…
Read More...

Flex Pharma announced positive topline data for FLX-787 from its exploratory Phase 2 trial in MS patients with frequent muscle cramps/spasms and spasticity. “MS patients frequently…
Read More...

SetPoint Medical announced that it has launched a pilot trial for patients with drug refractory rheumatoid arthritis (RA) in the U.S. The multi-center study, “A Randomized Controlled…
Read More...

Acorda Therapeutics announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA. Acorda is seeking marketing approval…
Read More...

FORMA Therapeutics and Arpeggio Biosciences announced a collaboration to utilize Arpeggio Biosciences’ proprietary technology to supplement FORMA’s analysis of the biological effects of…
Read More...

PharmaCyte Biotech, Inc. announced that it has filed a U.S. patent application with the United States Patent and Trademark Office (USPTO) to protect its therapy to treat cancerous…
Read More...

3P Biopharmaceuticals and Intervacc complete manufacturing agreement for new vaccine against equine strangles 3P Biopharmaceuticals and the Swedish company Intervacc have now…
Read More...

Astellas Pharma and Seattle Genetics announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug…
Read More...

Shire plc and NanoMedSyn announced that the companies have entered into a preclinical research collaboration to evaluate a potential ERT using NanoMedSyn's proprietary synthetic…
Read More...

Teva Pharmaceutical Industries Ltd., announced the launch of a generic version of ALOXI®1 (palonosetron HCI) injection, 0.25 mg/5 mL, in the United States. Palonosetron hydrochloride…
Read More...

Prothena Corporation announced a global collaboration with Celgene Corporation to develop new therapies for a broad range of neurodegenerative diseases. The multi-year research and…
Read More...

Regeneron Pharmaceuticals and Alnylam Pharmaceuticals announced a collaboration to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis (NASH) and…
Read More...

Seattle Genetics announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) in combination with chemotherapy in adult patients with…
Read More...

Merck announced the appointment of Jennifer Zachary as general counsel, effective April 16, 2018. Zachary will be responsible for Merck’s global legal, security and aviation, and…
Read More...

Horizon Discovery Group announces that one of the licensees to its Bioproduction cell line technology has used Horizon’s cell line as part of a successful Investigational New Drug (IND)…
Read More...

BIOASIS TECHNOLOGIES announced that Dr. Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE, has been appointed as chair of the board of directors. She takes over from former board chair…
Read More...

Symbiotix Biotherapies announced that it has entered into a license agreement with Harvard University. Under the agreement, Symbiotix gains access to a portfolio of intellectual…
Read More...